
Karl Winckel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6051715/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Clozapine use and prevalence in Australia 2016–2020. Australian and New Zealand Journal of Psychiatry, 2022, 56, 305-306.	2.3	4
2	Evaluation of the duration of dualâ€antiplatelet therapy after percutaneous coronary intervention: a retrospective audit on the compliance with guidelines or cardiologist recommendation. Journal of Pharmacy Practice and Research, 2022, 52, 42-48.	0.8	0
3	Estimation of cardiac QTc intervals in people prescribed antipsychotics: a comparison of correction factors. Therapeutic Advances in Psychopharmacology, 2022, 12, 204512532211049.	2.7	4
4	Metformin reduces 12-month change in body weight among people newly commenced on clozapine: a retrospective naturalistic cohort study. Therapeutic Advances in Psychopharmacology, 2021, 11, 204512532110006.	2.7	4
5	Does Switching Antipsychotics Ameliorate Weight Gain in Patients With Severe Mental Illness? A Systematic Review and Meta-analysis. Schizophrenia Bulletin, 2021, 47, 948-958.	4.3	26
6	Bazett's correction formula overestimates the corrected QT among patients with antipsychotic induced tachycardia. Schizophrenia Research, 2021, 231, 22-23.	2.0	3
7	Time to rethink our approach to the Pharmaceutical Benefits Scheme (PBS) listing of medicines: the case of pregabalin. Australian Health Review, 2021, 45, 261.	1.1	0
8	A retrospective review examining intravenous iron infusion dosing methods. Journal of Pharmacy Practice and Research, 2021, 51, 225-230.	0.8	0
9	Unfractionated heparin dosing in obese patients. International Journal of Clinical Pharmacy, 2020, 42, 462-473.	2.1	6
10	Comment On: "Stratifying Therapeutic Enoxaparin Dose in Morbidly Obese Patients by BMI Class: A Retrospective Cohort Study― Clinical Drug Investigation, 2020, 40, 287-288.	2.2	1
11	Evaluation of weight based enoxaparin dosing on anti-Xa concentrations in patients with obesity. Journal of Thrombosis and Thrombolysis, 2019, 48, 387-393.	2.1	9
12	Clozapine-related neutropenia, myocarditis and cardiomyopathy adverse event reports in Australia 1993–2014. Psychopharmacology, 2018, 235, 1915-1921.	3.1	17
13	Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes. Journal of Psychopharmacology, 2016, 30, 227-236.	4.0	37
14	Treatment of clozapine-associated obesity and diabetes with exenatide (CODEX) in adults with schizophrenia: study protocol for a pilot randomised controlled trial. BJPsych Open, 2015, 1, 67-73.	0.7	12
15	Clozapine in the community: Improved access or risky free-for-all?. Australian and New Zealand Journal of Psychiatry, 2015, 49, 863-865.	2.3	4
16	Comparison of prescribing criteria in hospitalised Australian elderly. Pharmacy Practice, 2010, 8, 132-8.	1.5	12